SERUM TRANSFORMİNG GROWTH FACTOR BETA 1 (TGF-Β1) LEVELS IN PANCREATIC ADENOCARCINOMA PATIENTS

Objective: the transforming growth factor beta 1 (tgf-β1) is a regulatory cytokine in many tumors. in this study, we aimed to determine the clinical significance of serum tgf- β1 levels in patients with pancreatic adenocarcinoma (pa).materials and methods: thirty-three patients with a histopathologically confirmed pa diagnosis and sex- and age-matched 30 healthy controls were included into the current study. serum tgf-β1 levels were measured using the elisa method.results: median age was 59 (range, 32-84). of the patients, 61% were male, 70% had good performance status, and 68% had tumors localized at the head of the pancreas. pancreaticoduodenectomy and palliative surgery were performed in 5 (15%) and 4 (12%) of the 9 (27%) patients who underwent surgical procedure. serum tgf-β1 levels were found to be significantly higher in patients compared with the control group (p<0.001). a significant correlation between serum tgf-β1 levels and clinico-pathological parameters including age, gender, performance status, tumor locatization, tumor size, metastasis, chemotherapy response, and laboratory parameters was not detected (p>0.05). hightgf-β1 levels seems to predict better survival (p=0.09) although it was not found significant.conclusions: serum tgf-β1 level is a diagnostic biomarker for patients with pa. however, it has neither predictive nor prognostic value in this group of patients